ESTRO 2024 - Abstract Book

S437

Clinical - Biomarkers

ESTRO 2024

1470

Digital Poster

Prognostic significance of IGF-1in HCC patients undergoing SBRT

Ahmed Allam Mohamed 1 , Marie-Luise Berres 2 , Christian Trautwein 2 , Biney Pal Singh 1 , Michael Eble 1

1 RWTH Aachen University Hospital, Radiation Oncology Department, Aachen, Germany. 2 RWTH Aachen University Hospital, Gastroenterology, Hepatology and Infectious Diseases Department, Aachen, Germany

Purpose/Objective:

Insulin-like growth factor (IGF-1) is a single-chain polypeptide hormone released in response to growth hormone. It operates in an autocrine/paracrine fashion, playing a crucial role in stimulating longitudinal growth and regulating metabolic functions. Approximately 75% of the circulating IGF-1 is synthesized by hepatocytes. Mechanistically, IGF-1 deficiency is central to early-stage liver damage and cirrhosis, with its serum level serving as a reflection of the hepatic reserve (1). This has led to the utilization of serum IGF-1 level as a prognostic tool in managing HCC, particularly in transarterial chemoembolization TACE (2) and systemic treatments (3). To the best of our knowledge, the potential prognostic implications of IGF-1 with stereotactic body radiotherapy (SBRT) have not been previously explored.

Material/Methods:

IGF-1 serum level was routinely collected from HCC patients prior to SBRT between May 2021 and July 2023. Our study assessed the correlation of IGF-1 level to various factors, including Child-Pugh Score (CPS), Tumor volume, Age, Performance status, and Alpha-Fetoprotein (AFP). Additionally, we employed Receiver Operating Characteristic (ROC) analysis to determine an optimal cut-off point enabling us to categorize the patients into “IGF 1 low” and “IGF-1 high” groups. Subsequently, we compared these two groups in terms of overall survival (OS) and Progression-Free Survival (PFS).

Results: